Search
N-acetyltyrosine
go.drugbank.com/drugs/DB11102ApprovedInvestigationalN-acetyltyrosine is administered as parenteral nutrition or intravenous infusion due to its enhanced solubility compared to tyrosine [A32652]. … N-acetyltyrosine, also referred to as N-acetyl-L-tyrosine, is used in place of as a tyrosine precursor. [DB00135] is a non-essential amino acid with a polar side group.
Anastrozole
go.drugbank.com/drugs/DB01217ApprovedInvestigational[L8863] Anastrozole is also related to [exemestane], a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated adverse effects such as weight gain and … as compared to earlier estrogen receptor modulators such as [tamoxifen].
Tisagenlecleucel
go.drugbank.com/drugs/DB13881ApprovedInvestigationalIt was granted approval by FDA in August 2017 under the market name Kymriah. … These CD19-directed chimeric antigen receptors (CD19 CAR-T cells) direct the T cells to target and kill leukemia cells that express CD19 on the cell surface.
Categories: Genetically-modified Autologous T CellsSynonyms: Tisagenlecleucel-T, CAR.CD19-Redirected T cellsLithium cation
go.drugbank.com/drugs/DB01356ApprovedInvestigationalWithdrawnLithium was used during the 19th century to treat gout. Lithium salts such as lithium carbonate (Li2CO3), lithium citrate, and lithium orotate are mood stabilizers. … Lithium can also be used to augment other antidepressant drugs. It is also sometimes prescribed as a preventive treatment for migraine disease and cluster headaches.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeGuanoxan
go.drugbank.com/drugs/DB13211ApprovedGuanoxan was approved in the UK but was withdrawn from the market due to hepatotoxicity. … Guanoxan is an antihypertensive agent similar in its mechanism of action to guanethidine; may cause liver damage.
Etranacogene dezaparvovec
go.drugbank.com/drugs/DB16791ApprovedInvestigational[L44161] Men are most likely to experience symptomatic illness due to the X-linked provenance of the disorder. … [L45255] Etranacogene dezaparvovec was approved by the EMA in February 2023[L45439,L45444] and by Health Canada in October 2023.[L48801]
Nateglinide
go.drugbank.com/drugs/DB00731ApprovedThe average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. … It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release.
Lunsotogene parvec
go.drugbank.com/drugs/DB18278ApprovedInvestigational[L56137] It acts by delivering functional copies of the human _OTOF_ gene specifically to inner hair cells via an engineered hair-cell-specific Myo15 promoter, which restores essential synaptic transmission … Lunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss.
Synonyms: DB-OTOTaurine
go.drugbank.com/drugs/DB01956ApprovedInvestigationalNutraceutical[A31396] This conditional amino acid can be either be manufactured by the body or obtained in the diet mainly by the consumption of fish and meat. … [L1058] The supplements containing taurine were FDA approved by 1984 and they are hypertonic injections composed by cristalline amino acids.[FDA label]
Pramlintide
go.drugbank.com/drugs/DB01278ApprovedInvestigationalPramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals.